Horizon Two: HR NDMM (MMRC-100)

The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an integrated and patient-centric clinical research platform that enables longitudinal learning and sharing of knowledge and investigates multiple novel therapeutic strategies within one trial platform.

Trial Details

NCT ID

NCT07053436

Phase

PHASE2

Sponsor

Multiple Myeloma Research Consortium

Status

RECRUITING

Cancer Type

Newly Diagnosed Multiple Myeloma

Interventions

Bispecific Monoclonal Antibody and Triplet Therapy
Monoclonal Antibody with Stem Cell Transplant

Locations (sample)

Atlanta, Georgia, United States|33.749,-84.38798
Chicago, Illinois, United States|41.85003,-87.65005
Detroit, Michigan, United States|42.33143,-83.04575
Rochester, Minnesota, United States|44.02163,-92.4699
St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

Voluntarily agree to participate by giving written informed consent
≥18 years of age
Symptomatic and transplant eligible newly diagnosed multiple myeloma histologically confirmed per IMWG criteria that is high-risk as defined by at …
Del(17p) (CCF ≥ 20%, by analyses conducted on CD138-positive/purified cells) and/or TP53 mutation assessed by NGS

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →